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Abstract
The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor
pyrrolopyridooxazepinone (PPO) derivative, (+/-)-PPO294, was shown to be active toward wild type
and mutated HIV-1 RT and to act synergistically in combination with 3'-azido-3'-deoxythymidine
(Campiani, G., Morelli, E., Fabbrini, M., Nacci, V., Greco, G., Novellino, E., Ramunno, A., Maga, G.,
Spadari, S., Caliendo, G., Bergamini, A., Faggioli, E., Uccella, I., Bolacchi, F., Marini, S., (1999) J.
Med. Chem. 42, 4462-4470). The (+/-)-PPO294 racemate was resolved into its pure enantiomers, and
the absolute configuration was determined by x-ray analysis. Only one enantiomer, (R)-(-)-PPO464,
displayed antiviral activity against both the wild type and the K103N mutant HIV-1 RT and was found
to interact exclusively with the reaction intermediate formed by RT complexed with both the DNA and
the nucleotide substrates. Being the first compound of its class to display this behavior, (R)-(-)-PPO464
is the representative of a novel generation of nonnucleoside inhibitors. (R)-(-)-PPO464 showed
significant synergism when tested in combination with other RT inhibitors and efficiently inhibited viral
replication when tested against the laboratory strain HIV-1 IIIB or against either wild type or
multidrug-resistant clinical isolates. Pharmacokinetic studies in mice and rats showed a more favorable
profile for (R)-(-)-PPO464 than for the corresponding racemate. (R)-(-)-PPO464 was also found to
easily cross the blood-brain barrier. The coadministration of the HIV-1 protease inhibitor ritonavir
increased the bioavailability of (R)-(-)-PPO464, having little effect on its plasma and brain elimination
rates.
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The human immunodeficiency virus type 1 (HIV-1)
nonnucleoside reverse transcriptase (RT) inhibitor pyr-
rolopyridooxazepinone (PPO) derivative, ()-PPO294,
was shown to be active toward wild type and mutated
HIV-1 RT and to act synergistically in combination with
3-azido-3-deoxythymidine (Campiani, G., Morelli, E.,
Fabbrini, M., Nacci, V., Greco, G., Novellino, E.,
Ramunno, A., Maga, G., Spadari, S., Caliendo, G.,
Bergamini, A., Faggioli, E., Uccella, I., Bolacchi, F.,
Marini, S., (1999) J. Med. Chem. 42, 4462–4470). The ()-
PPO294 racemate was resolved into its pure enanti-
omers, and the absolute configuration was determined
by x-ray analysis. Only one enantiomer, (R)-()-PPO464,
displayed antiviral activity against both the wild type
and the K103N mutant HIV-1 RT and was found to inter-
act exclusively with the reaction intermediate formed
by RT complexed with both the DNA and the nucleotide
substrates. Being the first compound of its class to dis-
play this behavior, (R)-()-PPO464 is the representative
of a novel generation of nonnucleoside inhibitors. (R)-
()-PPO464 showed significant synergism when tested
in combination with other RT inhibitors and efficiently
inhibited viral replication when tested against the lab-
oratory strain HIV-1 IIIB or against either wild type or
multidrug-resistant clinical isolates. Pharmacokinetic
studies in mice and rats showed a more favorable profile
for (R)-()-PPO464 than for the corresponding race-
mate. (R)-()-PPO464 was also found to easily cross the
blood-brain barrier. The coadministration of the HIV-1
protease inhibitor ritonavir increased the bioavailabil-
ity of (R)-()-PPO464, having little effect on its plasma
and brain elimination rates.
The virus-encoded HIV-11 reverse transcriptase (RT) is es-
sential for the viral replication cycle and therefore represents a
logical target for antiviral chemotherapy (1, 2). Recently, a
class of inhibitors targeted to the viral RT, the so-called NNR-
TIs, have gained a definitive place in the treatment of HIV-1
infections along with NRTIs and PIs (3). These compounds,
despite their different chemical structures, are highly specific
for HIV-1 RT and bind to the enzyme at the same allosteric site
close to, but distinct from, the catalytic site, behaving as typi-
cally noncompetitive inhibitors with respect to the different
substrates of the polymerization reaction. The NNRTIs nevi-
rapine, delavirdine, and the most recently licensed, efavirenz
(Fig. 1), are currently used in clinical practice. First generation
NNRTIs, such as nevirapine, were identified by extensive ran-
dom screening of different molecules. However, given their very
similar mode of action and their unique binding site in the RT
enzyme, the occurrence of just a few single amino acid substi-
tutions in the RT gene can confer resistance to most of the first
generation NNRTIs such as nevirapine (4). Accumulating
knowledge about the resistance mutations selected by these
compounds during chemotherapy as well as the resolution of
crystallographic structures of different complexes of HIV-1 RT
bound to NNRTIs (5, 6) allowed the rational design of second
generation molecules, such as efavirenz, with improved po-
tency against the wild type enzyme and several resistant forms
(7). However, the single K103N mutation can still confer cross-
resistance to most, if not all, of the members of this subclass (8).
Thus, the continuous challenge posed by the emergence of
HIV-1-resistant mutants highlights the need to develop third
generation inhibitors with yet more favorable binding proper-
ties to the wild type and mutated enzymes (9).
Triple drug combinations have been shown to suppress
plasma HIV-1 load for periods of time significantly longer than
monotherapy or dual therapy, allowing CD4T cell increase,
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significant immune system function restoration, and clinical
improvement (10). In particular, the results of clinical trials
employing NNRTIs as components of highly active antiretrovi-
ral therapy in combination with NRTIs and/or PIs showed that
NNRTIs often act synergistically with NRTIs and, due to pos-
itive pharmacokinetic properties, allow simplified administra-
tion schedules with a substantial improvement in patients’
adherence to treatment (11). Moreover, NNRTIs are character-
ized by less severe adverse effects than NRTIs or PIs (12).
Several factors may restrict the selection of antiviral drugs to
be used in the combination therapy, such as drug compatibili-
ties, adverse side effects, and cross-resistance (13, 14). There-
fore, the development of novel NNRTIs with improved phar-
macological, pharmacokinetic, and drug resistance mutation
profiles, is critical for a more successful application of NNRTIs
in combination therapy. In an effort aimed to identify new lead
molecules for the development of NNRTIs with high inhibitory
activity against wild type and mutated RT, we have selected
the PPO derivative ()-PPO294 (Fig. 1) as a promising lead
compound (15). In the present work, we have characterized the
mechanism of action of both ()- and ()-enantiomers of ()-
PPO294 against HIV-1 recombinant RT enzymes and viral
isolates, either wild type or bearing the K103N mutation. Our
results show that only the ()-enantiomer (R)-()-PPO464
(Fig. 1) retained full antienzymatic and antiviral activity, act-
ing through a distinct mechanism with respect to other NNR-
TIs. These novel properties make (R)-()-PPO464 a promising
lead for the synthesis of more active third generation
compounds.
MATERIALS AND METHODS
Chemistry
Melting points were determined using a Buchi melting point B-540
apparatus and were uncorrected. IR spectra were taken with
PerkinElmer Life Sciences 398 and FT 1600 spectrophotometers. 1H
NMR spectra were recorded on a Bruker 200-MHz spectrometer or on a
Gemini Varian 200-MHz spectrometer with TMS as internal standard;
the values of the chemical shifts () are given in ppm, and coupling
constant (J) is given in Hz.
The reactions were carried out in an argon atmosphere. TLCs were
performed on silica gel plates (Riedel-de-Haen; Art.37341). Merck silica
gel (Kieselgel 60) was used for the flash chromatography (230–400-
mesh) column. Yields refer to purified products and are not optimized.
Organic extracts were dried over MgSO4, and the solvents were
removed under reduced pressure. Optical rotations were measured at
room temperature on a PerkinElmer Life Sciences model 241 polarim-
eter. The racemic PPO294 was obtained as described in Ref. 15. Ele-
mental analyses were performed on a PerkinElmer Life Sciences 240C
elemental analyzer or on a CHNS EA 1110 Thermoquest-analyzer and
the results are within 0.4% of the theoretical values. Mass spectra
were measured on a double focusing mass spectrometer VG 70–250S
(VG Analytical Ltd., Manchester, UK) under electron ionization condi-
tions (70 eV and accelerating voltage of 8 KV) and on a Waters Platform
LC Micromass spectrometer. The racemate was resolved by a semi-
preparative HPLC Waters model 600 mass spectrometer equipped with
a Rheodyne model 7125 injector valve and a 200-l fixed loop, UV
detector 2487 (Waters Chromatography, Milford, MA), and RI detector
model Waters 410. Purity of enantiomers was evaluated by the analyt-
ical HPLC Alliance 2690 coupled to a UV detector 2487 (Waters Chro-
matography). The semipreparative chromatographic column was a
stainless steel column (10-m particle size) (250  20 mm ID) packed
with Chiralpak-AD, amilose carbamate supported on silica gel, pur-
chased from Daicel Chemical Industries, Ltd. (Tokyo, Japan). Flow rate
of mobile phase was 5 ml/min. The column was kept inside a refriger-
ating bath at a controlled temperature of 0 °C. The analytical chromato-
graphic column was a stainless steel column (5 m 250  4.6 mm ID)
packed with Chiralpak-AD, amilose carbamate supported on silica gel,
purchased from Merck.
Racemate Resolution
A solution of the racemic compound ()-PPO294 (20 mg, 0.066 mmol)
in 1 ml of hexanes/ethanol/triethylamine (95:5:0.1), after filtration on a
0.45-m Millipore Corp. filter, was resolved at 0 °C on a semiprepara-
tive Chiralpak-AD (10 m, 20  250 mm) using hexanes/ethanol/tri-
ethylamine (95:5:0.1) as eluent (5 ml/min). The effluent was monitored
at   304 nm, and the enantiomers ()-PPO463 and ()-PPO464
eluted with retention times of 33.7 and 38.4 min, respectively. The
fractions were collected and concentrated to afford ()-PPO463 (8.7 mg,
87%, 100% enantiomeric excess) and (-)-PPO464 (8.9 mg, 89%, 99.3%
enantiomeric excess) as colorless liquids. The purity of the enantiomers
was evaluated by analytical HPLC using the same mobile phase (1
ml/min) (retention times: ()-PPO463 peak, 8.0 min; ()-PPO464 peak,
8.7 min). Solutions collected were dried with a vacuum pump, since an
oily residue was obtained. ()-PPO463/()-PPO464: 1H NMR (CDCl3) 
1.10 (t, 3H, J  7.0 Hz), 2.45 (q, 2H, J  7.1 Hz), 6.49 (m, 1H), 7.03 (m,
1H), 7.10–7.30 (m, 5H), 7.37 (m, 1H), 7.51 (m, 1H), 7.94 (m, 1H), 8.07
(m, 1H). MS (EI) m/z: 304 (M). ()-PPO463: []D
22  56.7 (c  0.56
(CH2Cl2)); ()-PPO464: []D
22  56.5 (c  0.57 (CH2Cl2)). Anal. Calcd.
for (C19H16N2O2): C, 74.98; H, 5.30; N, 9.20. Found: for ()-PPO464: C,
75.40; H, 6.65; N, 8.96; for ()-PPO463: C, 75.07; H, 6.05; N, 9.07.
Synthesis of ()-9-Bromo-6-ethyl-6-phenylpyrrolo[1,2-d]pyrido[3,2-
b][1,4]oxazepin-7(6H)-one, ()-PPO600
To a solution of ()-PPO463 (65 mg, 0.214 mmol) in anhydrous
tetrahydrofuran (5 ml) cooled at 70 °C was added N-bromosuccini-
mide (38 mg, 0.214 mmol). The reaction mixture was stirred vigorously
for 1.5 h at 70 °C and then was gradually wormed to room tempera-
ture. After 16 h at room temperature, the solvent was removed in vacuo,
and the residue was taken up in dichloromethane; the organic layer was
washed with brine, dried, and concentrated. The crude product was
purified by flash chromatography using dichloromethane/hexane (8:2)
as eluent. Recrystallization from hexane gave 31 mg (38%) of pure
()-PPO600 as colorless prisms (mp 155–156 °C). IR (CHCl3) 1654
cm1; 1H NMR (CDCl3)  1.08 (t, 3H, J  7.0 Hz), 2.42 (q, 2H, J  7.1
Hz), 7.04 (dd, 1H, J  7.9, 4.8 Hz), 7.19 (m, 5H), 7.35–7.43 (m, 2H), 7.94
(m, 1H), 8.04 (m, 1H). MS (EI) m/z (%): 382/384 (M), 248/250 (100).
[]22D 89 (c  3.2 (CHCl3)). Anal. Calcd. for (C19H15BrN2O2):
C,59.55; H, 3.95; N, 7.31. Found: C, 59.37; H, 3.72; N, 7.18.
X-ray Crystallography
Single crystals of ()-PPO600 were obtained by dissolving 20 mg in
methanol and allowing the solution to concentrate at room
temperature.
A colorless single crystal of ()-PPO600 (C19H15N2BrO2, molecular
weight 383.2) with approximate dimensions 0.15  0.10  0.15 mm was
submitted to x-ray data collection on a Siemens P4 four-circle diffrac-
tometer with graphite monochromated Mo-K radiation (  0.71069
Å). Lattice parameters were determined by least-squares refinement on
47 randomly selected and automatically centered reflections. The /2
scan technique was used in the data collection in the 4  2  50° scan
range.
Crystal system: orthorhombic; space group: P212121; a  8.111(1),
b  13.965(2), c  15.087(2) Å, V  1708.9(4) Å3, Z  4, Dc  1.490
g/cm3. 3469 reflections were collected at 22 °C, of which 3004 are unique
(Rint  0.07). Absorption correction obtained by /2 scans was applied.
The structure was solved by direct methods implemented in the
SHELX-97 program (39). The refinement was carried out by full matrix
anisotropic least-squares on F2 for all reflections for nonhydrogen at-
oms by using the SHELX-97 program (39).
The absolute configuration of the chiral center at the pyridooxaz-
epine nucleus was made by the refined Flack parameter (16). It resulted
as S.
The final refinement converged to R1  0.078, wR2  0.129 for I 
2I, goodness of fit  1.02. Minimum and maximum height in last 		
map of 0.58 and 0.47 eÅ3. On the basis of the stereochemistry of
()-PPO600 was assigned the stereochemistry of ()-PPO463 and of
()-PPO464 (i.e. (S)- and (R)-, respectively).
Chemicals
[3H]dTTP (40 Ci/mmol) was from Amersham Pharmacia Biotech, and
unlabeled dNTPs were from Roche Molecular Biochemicals. Whatman
was the supplier of the GF/C filters. All other reagents were of analyt-
ical grade and purchased from Merck or Fluka.
Nucleic Acid Substrates
The homopolymer poly(rA) (Amersham Pharmacia Biotech) was
mixed at weight ratios in nucleotides of 10:1, to the oligomer
oligo(dT)12–18 (Amersham Pharmacia Biotech) in 20 mM Tris-HCl (pH
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8.0), containing 20 mM KCl and 1 mM EDTA, heated at 65 °C for 5 min,
and then slowly cooled at room temperature.
Expression and Purification of Recombinant HIV-1 RT Forms
Recombinant RT was expressed and purified to 95% purity as
described (21) and had a specific activity on poly(rA)/oligo(dT) (see
below) of 75,670 units/mg; 1 unit of DNA polymerase activity corre-
sponds to the incorporation of 1 nmol of dNMP into acid-precipitable
material in 60 min at 37 °C.
HIV-1 RT RNA-dependent DNA Polymerase Activity Assay
RNA-dependent DNA polymerase activity was assayed as follows; a
final volume of 25 l contained buffer A (50 mM Tris-HCl, pH 7.5, 1 mM
DTT, 0.2 mg/ml bovine serum albumin, 4% glycerol), 10 mM MgCl2, 0.5
g of poly(rA)/oligo(dT)10:1 (corresponding to 0.3 M 3-OH ends), 10 M
[3H]dTTP (1 Ci/mmol), and 2–4 nM RT. Reactions were incubated for 10
min at 37 °C. 20-l aliquots were then spotted on GF/C glass fiber
filters, which were immediately immersed in 5% ice-cold trichloroacetic
acid. Filters were washed twice in 5% ice-cold trichloroacetic acid and
once in ethanol for 5 min and dried, and acid-precipitable radioactivity
was quantitated by scintillation counting.
Inhibition Assays
Reactions were performed under the conditions described for the
HIV-1 RT RNA-dependent DNA polymerase activity assay. Incorpora-
tion of radioactive dTTP into poly(rA)/oligo(dT) at different concentra-
tions of DNA or dNTP was monitored in the presence of increasing
amounts of inhibitor as indicated in the figure legends. Data were then
plotted according to Dixon.
Kinetics of (R)-()-PPO464 Binding
HIV-1 RT (20–40 nM), either wild type or mutated, was incubated for
2 min at 37 °C in a final volume of 4 l in the presence of poly(rA)/
oligo(dT), corresponding to 15 nM 3-OH ends, Buffer A, and 10 mM
MgCl2. ()-PPO464 was then added to a final volume of 5 l, at a
concentration at which [E:I]/[E0]  (1  1/(1  [I]/Ki))  0.9. Then 145
l of a mix containing Buffer A, 10 mM MgCl2, and 10 M [
3H]dTTP (1
Ci/mmol) were added at different time points. After an additional 10
min of incubation at 37 °C, 50-l aliquots were spotted on GF/C filters,
and acid-precipitable radioactivity was measured as described for the
HIV-1 RT RNA-dependent DNA polymerase activity assay. The quan-
tity (v0  vt)/v0, representing the normalized difference between the
amount of dTTP incorporated at the zero time point and at the different
time points, was then plotted against time.
Thermodynamic Parameter Determination
Reactions were carried out at different temperatures under the con-
ditions described for the inhibition assays. Separate incubations were
performed for each temperature in a HAAKE E8 thermostated water
bath. Ki values for nevirapine inhibition at the different temperatures
were then calculated as described (see below).
Steady-state Kinetic Model for the Inhibition of the RT Reaction
by (R)-()-PPO464
A simplified reaction pathway was assumed for the RT-catalyzed
reaction. As shown in Scheme 1A, RT follows an ordered bireactant
mechanism, where TP binds first with an equilibrium dissociation
constant Km(TP), followed by dNTP binding with the corresponding
equilibrium constant Km(dNTP), to form the catalytically competent
ternary complex that reacts with the substrate to give products RTP
with an overall reaction rate kcat. NNRTI binding was assumed to be
possible in principle to each reaction intermediate: free enzyme (RT),
binary complex (RTTP), and ternary complex (RTTPdNTP). The for-
mation of the corresponding inhibited complexes RTI, RTTPI, and
RTTPdNTPI is driven by the equilibrium dissociation constants Kd(E),
Kd(bin), and Kd(ter), respectively. Each equilibrium constant is defined
as the ratio between the corresponding inhibitor dissociation and asso-
ciation rates, such as Kd  koff/kon. Binding constants of the TP and
dNTP substrates to the RTI and RTITP complexes were defined as
Km(TP) and Km(dNTP), respectively, and were assumed to be equal to
the Km(TP) and Km(dNTP) values for the uninhibited complexes.
Scheme 1B illustrates the experimentally used conditions for inhibitor
binding studies. With saturating dNTP and variable TP (Scheme 1B,
right part), under the assumption of rapid equilibrium binding of dNTP,
only two enzymatic forms exist at the steady state: the free enzyme (RT)
and the ternary complex. Inhibitor binding is driven by the correspond-
ing equilibrium constants Kd(E) and Kd(ter). When Kd(E)  Kd(ter), the
inhibition is fully noncompetitive; with Kd(E)  Kd(ter), inhibition is
uncompetitive at low [I], since only the RTTPdNTPI complex can be
formed, becoming mixed-noncompetitive at higher [I], when also the
RTI complex is formed. When Kd(E)  Kd(ter), inhibition is fully
uncompetitive, since inhibitor binding is determined exclusively by the
degree of saturation of RT with its substrates. Similarly, with saturat-
ing TP and variable dNTP (Scheme 1B, left part), only the binary RTTP
and the ternary RTTPdNTP complexes exist at the steady state. In-
hibitor binding can be described by the equilibrium dissociation con-
stants Kd(bin) and Kd(ter) for the RTTPI and RTTPdNTPI complexes,
respectively. Also, under these conditions the following relationships
hold: Kd(bin)  Kd(ter), noncompetitive inhibition; Kd(bin)  Kd(ter),
mixed noncompetitive inhibition; Kd(bin)  Kd(ter), fully uncompeti-
tive inhibition.
Kinetic Parameter Calculation
All values were calculated by nonlinear least squares computer fit-
ting of the experimental data to the appropriate rate equations. Ki
values were calculated according to the equation for uncompetitive
inhibition,
v
 Vm/

Km/S]) 
1 I]/Ki
obs))) (Eq. 1)
where Ki(obs) is the apparent equilibrium dissociation constant of the
inhibitor from the ternary complex as shown in Scheme 1, measured at
different substrate concentrations.
Dependence of the Ki(obs) on the substrate concentrations was fitted
to the equation,
Ki(obs) 
 
1 
Km/S]))Kd
ter) (Eq. 2)
where Kd(ter) is the true equilibrium dissociation constant of the inhib-
itor from the ternary complex at infinite substrate concentration.
Dose-dependent inhibition at different substrate concentrations was
fitted to the equation,
E
 
Emax([I]/Ki
obs))m/
1 
Ki
obs)/[I]m (Eq. 3)
where E is the observed inhibition (percentage), Emax is the inhibition at
infinite inhibitor concentration, and Ki(obs) is the apparent equilibrium
dissociation constant of the inhibitor from the ternary complex as
shown in Scheme 1, measured at different substrate concentrations.
SCHEME 1
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For determination of inhibitor binding kinetics, kapp values were
determined by fitting the experimental data to the single exponential
equation,

v0  vt/v0 
 A
1 e
kappt (Eq. 4)
where A is a constant and t represents time.
For the thermodynamic parameter calculations, 	H[ter:I] and 	S[ter:I]
values were determined according to the van’t Hoff equation,
ln (1/Ki
obs))
	Hter:I]/RT 	Ster:I]/R (Eq. 5)
where R is the gas constant, and T is the absolute temperature (Kelvin).
	G[ter:I] was calculated from the equation,
	Gter:I] 
 	Hter:I]  T	Ster:I] (Eq. 6)
Determination of Synergy
Two different approaches were employed. The first method was
based on the Lowe additivity model, according to Ref. 17. Dose-response
curves for the interaction between AZTTP, nevirapine, and (R)-()-
PPO464 were assumed to follow Hill’s model and were generated by
fitting the experimental data to the equation,
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where E is the observed effect (percentage of activity), Econ is the control
effect (activity in the absence of the inhibitor), D50 is the 50% inhibitory
concentration, and m is a sigmoidicity parameter. The interaction index
I was then calculated according to Berenbaum by the equation,
I
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where D1 and D2 are the concentrations of the drugs giving 50% inhi-
bition when tested in the combination D1  D2, and D50(1) and D50(2) are
the concentrations of each drug giving 50% inhibition when tested
individually. A value for I  1 indicates synergy, I  1 indicates
antagonism, and I  1 indicates additivity, according to the Lowe
additivity model.
For combination of two drugs at a fixed molar ratio (R  [drug
1]/[drug 2]), D1 and D2 values were calculated from the D50 value
derived from Equation 7, with (D1  D2)  D50 and D1  RD2.
Expected D1, D2, and Di values for the combination of i drugs under
the null reference hypothesis of no interaction were derived by inserting
estimated D50 and m values for each drug in the combination in the
specific form of the Lowe additivity equation, which assumes that
Equation 7 is appropriate for each drug individually (17).
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The null reference hypothesis of no interaction (Equation 9) corre-
sponded to I  1.
All of the analysis was based on the results of three independent
experiments for each drug combination, and the S.D. values for each
parameter estimate are indicated.
The second approach was based on the multiple drug effect analysis
of Chou and Talalay (18, 19). This method involves plotting dose-effect
curves for each agent and for one or more multiply diluted, fixed
combination of the agents using the “median effect” equation: fa/fu 
(D/Dm)
m. In this equation, D represents the dose, Dm is the dose re-
quired for 50% effect (e.g. 50% inhibition of viral replication), fa is the
fraction affected by the dose D, fu is the fraction unaffected, and m is a
coefficient signifying the sigmoidicity of the dose-effect curve. The dose-
effect curve is plotted using a logarithmic conversion of this equation
that determines the m and Dm values. Based on the slope of the
dose-effect curves, it can be decided whether the agents have mutually
exclusive effects (e.g. a similar mode of action) or mutually nonexclusive
effects (e.g. an independent mode of action). A “combination index” (CI)
is then determined using the equation,
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where (D50(1) represents the dose of agent 1 required to produce 50%
effect alone, and (D)1 is the dose of that agent required to produce the
same 50% effect in combination with (D)2. Similarly, (D50(2) is the dose
of agent 2 required to produce the same 50% effect alone, and (D)2 is the
dose required to produce the same effect in combination. If the agents
are mutually exclusive, then  is 0 (i.e. CI is the sum of two terms); if
mutually nonexclusive, then  is 1 (i.e. CI is the sum of three terms). If
it is uncertain whether the agents act in a similar or independent
manner, the formula may be solved in both ways. Values of CI less than
1 indicate synergy, values greater than 1 indicate antagonism, and
values equal to 1 indicate additive effect.
Viral Isolation and Drug Susceptibility Assay with Clinical
Isolates
The infectivity titer of HIV isolates was determined by end point
titration of peripheral blood mononuclear cell culture supernatants and
expressed as 50% tissue culture infective dose (TCID50) (37). In vitro
drug susceptibility assays were performed using a modified ACTG/
AIDS consensus method (38). Briefly, on day 0, 2000 TCID50 of virus
stock supernatant were inoculated on 2  105 peripheral blood mono-
nuclear cells growing in each well of a 96-well plate. After 4 h at 37 °C,
half of the supernatant was discarded and replaced with medium con-
taining the drug to achieve the required drug concentration. Plates
were then incubated at 37 °C in a 5% CO2 atmosphere. On day 4, half
of the supernatant was replaced with fresh medium containing the
appropriate drug concentration. On day 7, the supernatant of each well
was assayed for p24 antigen production. The 50% inhibitory dose (ID50)
was determined for each drug tested through dose-effect analysis of the
p24 value in the control wells (without drug) and the corresponding
wells in the presence of the drugs. In parallel, drug toxicity controls and
back virus titration were performed.
Pharmacokinetic Studies
Drug Administration and Plasma and Brain Sampling—Disposition
studies were done in male CD1 mice and CD-COBS rats weighing about
30 and 300 g, respectively (Charles River). Procedures involving ani-
mals and their care were conducted in conformity with the institutional
guidelines that are in compliance with national (D.L. n. 116, G.U.,
Suppl. 40, 18 February 1992, Circolare No. 8, G.U., 14 July 1994) and
international laws and policies (EEC Council Directive 86/609, OJ L
358,1, December 12, 1987; Guide for the Care and Use of Laboratory
Animals, United States National Research Council, 1996). A chronic
jugular cannula (PE-50 tubing) was implanted in each rat under chloral
hydrate anesthesia 24 h before the study started. Rats were given
compound ()-PPO294 subcutaneously or orally in PEG-400/ethanol/
Tween 80 (60:30:10, v/v/v), and serial blood samples were drawn at
various times. Samples were centrifuged, and the plasma was stored at
20 °C. At the end of the study (4 h after dosing), rats were killed by
decapitation under deep anesthesia, and brains were rapidly removed,
blotted with paper to remove excess surface blood, and stored at 20 °C
until analysis. Mice were given the active isomer of compound ()-
PPO294 only orally (20 mg/kg, dissolved as above). Some received 20
mg/kg ritonavir (dissolved in PEG-400/ethanol/water, 40:10:50 v/v/v) 30
min before the test compound. The animals were killed by decapitation
under deep anesthesia 15, 30, 60, 120, and 180 min after dosing. Plasma
and brain samples were processed as described for the rat. Rats toler-
ated the ()-PPO294 dose with no observable discomfort. Mice given
the (R)-()-PPO464 were slightly ataxic within the first 30–60 min of
dosing, and the effect was enhanced and prolonged by ritonavir
co-administration.
Drug Analysis—The test compound was extracted from plasma and
brain homogenates (methanol; 1 g/5 ml) and measured by high perform-
ance liquid chromatography with UV detection (300 nm) as previously
described (15). Separation was done on a Spheri-5 RP 18 Brownlee
column (25 cm  4.6 mm ID, 5-m particle size), with a New Guard
RP-18 5 m precolumn, at room temperature. The mobile phase was
CH3OH, 0.025 M CH3COONH4, n-propyl alcohol (63:36:1, v/v/v), buff-
ered at pH 5 with acetic acid. It was delivered isocratically at a flow rate
of 1.2 ml/min. The retention times are 20.2 min for compound ()-
PPO294 and 22.8 min for the structurally related internal standard
(15). The sensitivity limit was 0.15 nmol/ml or g, using 0.2 ml of plasma
or 200 mg of brain tissue. At this concentration, the coefficient of
variation was between 15 and 20%, and higher concentrations generally
gave a coefficient of variation less than 10% in both tissues. Over the
sampling interval, the plasma and brain area under the concentration-
time curve (AUCt) were determined using the linear trapezoidal rule.
Then the value was extrapolated to infinity (AUC), when possible, using
the terminal slope and the last plasma or brain concentration. The
elimination half-life (t1⁄2) was determined by the usual equation. The
maximum concentration (Cmax) and the time (tmax) of its occurrence
were read directly from the plasma and brain concentration-time data.
Plasma and brain concentrations of compound ()-PPO294 and its
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active isomer were expressed as mean  S.D. Differences between
vehicle- and ritonavir-treated animals were assessed using Student’s t
test.
RESULTS
(R)-()-PPO464 Is a Stereoselective, Uncompetitive Inhibitor
of Wild Type HIV-1 Reverse Transcriptase—The two () and
() enantiomers of ()-PPO294 were isolated in pure form from
a racemic preparation as described under “Materials and Meth-
ods.” The configuration of the chiral center was assessed on the
9-bromo derivative (()-PPO600) of the inactive enantiomer
()-PPO463 (Fig. 1). After determination of the absolute con-
figuration, the enantiomers were then indicated as (S)-()-
PPO463 and (R)-()-PPO464, respectively. When tested as in-
hibitors of WT HIV-1 RT, as shown in Fig. 2A, only the (R)-
()-PPO464 was effective as an inhibitor of the viral enzyme.
To determine its mode of action, the dependence of the inhibi-
tion on both the 3-OH TP (poly(rA)/oligo(dT)) and the dTTP
substrates was studied. In both cases, the kinetic parameters
Vm and Km were reduced in an inhibitor concentration-depend-
ent manner (Fig. 2, B and C, for poly(rA)/oligo(dT); data not
shown for dTTP), indicating a purely uncompetitive mecha-
nism of inhibition with respect to both substrates of the
reaction.
(R)-()-PPO464 Binds Specifically to the Ternary Complex of
HIV-1 Reverse Transcriptase with both the 3-OH and dNTP
Substrates—As outlined under “Materials and Methods,”
HIV-1 RT follows an obligatory ordered ternary complex-reac-
tant kinetic pathway for catalysis, where the 3-OH TP binds
first, followed by dNTP. According to this mechanism, under
the experimental conditions used, the uncompetitive inhibition
observed in dependence of both substrates suggested that the
inhibitor exclusively binds to the ternary complex formed by
RT bound to both the 3-OH TP and dNTP substrates. If true,
as a direct consequence, the potency of inhibition should be
dependent on the degree of saturation of the enzyme by both
substrates. As shown in Fig. 3, A and C, the potency of inhibi-
tion was increased by increasing concentrations of both the
3-OH TP (poly(rA)/oligo(dT)) and dTTP, indicating that (R)-
()-PPO464 was a specific inhibitor of the ternary complex
(RTTPdNTP). The equilibrium dissociation constant (Kd) of
the inhibitor from this complex was calculated from the de-
pendence of the observed inhibition constant (Ki(obs)) on the
substrate concentration, as shown in Fig. 3, B and D. The
calculated Kd values are reported in Table I.
(R)-()-PPO464 Inhibits Wild Type HIV-1 Reverse Tran-
scriptase and the Mutant Enzyme K103N with the Same Mech-
anism—As in the case of WT RT, only the (R)-()-PPO464 was
effective as an inhibitor of the RT mutant K103N, even if with
a reduced potency (Fig. 4A). The mechanism of inhibition was
again purely uncompetitive, with both the Km and Vm param-
eters decreasing in an inhibitor-dependent manner (Fig. 4, B
FIG. 1. Structures of the clinically used NNRTIs nevirapine,
efavirenz, and delavirdine and of the PPO series of compounds
used for this study. In the drawing of the structure of the compound
(S)-()-PPO600, the nonhydrogen atom ellipsoids enclose 50%
probability.
FIG. 2. Inhibition of wild type HIV-1 RT by (R)-()-PPO464.
Assays were performed under the conditions described under “Materi-
als and Methods.” A, inhibition of HIV-1 RT activity by the two enan-
tiomers (R)-()-PPO464 (triangles) and (S)-()-PPO463 (circles). B, plot
of the dependence of HIV-1 RT inhibition by (R)-()-PPO464 on the
3-OH concentration. When points were fitted to the uncompetitive
model of Equation 1, the sums of squares of errors (SSE) were 5.6, 21.2,
9.2, 0.22, and 2.7, respectively, for the curves obtained at (R)-()-
PPO464 concentrations of 0 (circles), 5 nM (squares), 20 nM (rhombics),
100 nM (triangles), and 200 nM (closed circles). The SSE for fitting to the
noncompetitive model were 5.5, 35.2, 19.8, 1.2, and 4.6, respectively,
whereas for the competitive model, SSE were 5.8, 58.7, 53.6, 3.1, and
8.3, respectively. C, plot of the dependence on the (R)-()-PPO464
concentration of HIV-1 RT Km (nM) and Vm (pmol 30 min
1) values for
the poly(rA)/oligo(dT) substrate. Curves were fitted to the following
equations: Km(obs)  Km/(1  [I]/Ki) and Vm(obs)  Vm/(1  [I]/Ki).
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and C). The potency of inhibition was increased by increasing
concentrations of the dNTP substrate (data not shown). Accord-
ing to Scheme 1, in the presence of saturating 3-OH TP con-
centrations, this reflects the exclusive binding of the inhibitor
to the ternary complex (RTTPdNTP). As shown in Fig. 4D, the
dependence of the Ki(obs) on the dNTP concentration allowed
an estimation of the inhibition constant Kd. Table I summa-
rizes the calculated kinetic parameters for the interaction of
WT RT and the K103N mutant with the 3-OH TP and dNTP
substrates and the (R)-()-PPO464 inhibitor.
(R)-()-PPO464 Effectively Inhibits Viral Replication of ei-
ther Wild Type or Multidrug-resistant Viral Isolates—When the
(R)-()-PPO464 inhibitor was tested against a WT HIV-1 IIIB
laboratory strain, it effectively suppressed viral replication
with an ID50 of 0.35 M. Interestingly, when similar experi-
ments were performed with a wild type clinical isolate from a
treatment-naive HIV-1-infected patient, the activity was even
higher (ID50  0.04 M) (Table I). The K103N substitution
conferred approximately 10-fold resistance toward the inhibi-
tor. When tested against a multidrug-resistant clinical isolate
harboring the M41L/K103N/T215Y mutations, (R)-()-PPO464
showed an ID50 of 3.4 M, which accounted for a 10-fold resist-
ance level with respect to the laboratory reference WT virus
HIV-1 IIIB and about 50-fold with respect to the wild type
clinical isolate (Table I). This difference could be due to genetic
polymorphisms between the genomic sequence of the reference
strain used either to generate the recombinant RT through
site-directed mutagenesis (HIV-1 HXB2) or in the antiprolif-
erative assay (HIV-1 IIIB) and the genome of the clinical iso-
late. However, the level of resistance to (R)-()-PPO464 of the
multidrug-resistant mutant virus was comparable with efa-
virenz and 4-fold lower than that of nevirapine and delavirdine
(Table II). (R)-()-PPO464 also effectively suppressed virus
replication in different HIV-1-infected cell lines with favorable
toxicity profiles (Table III).
Kinetic and Thermodynamic Characterization of (R)-()-
PPO464 Binding to HIV-1 Reverse Transcriptase—The ob-
served differences between the Kd values of (R)-()-PPO464 for
FIG. 3. Dependence of (R)-()-
PPO464 inhibition potency on the sub-
strate concentration. Assays were per-
formed under the conditions described
under “Materials and Methods.” A, (R)-()-
PPO464 inhibitory activity (Effect, E) on
HIV-1 RT at increasing 3-OH concentra-
tions. 3-OH concentrations tested were 5,
10, 20, 100, and 200 nM. B, dependence of
(R)-()-PPO464 inhibition constants
(Ki(obs)) on 3-OH concentrations. C, (R)-
()-PPO464 inhibitory activity (Effect, E)
on HIV-1 RT at increasing dTTP concen-
trations. dTTP concentrations tested were
0.5, 2, 10, and 20 M. D, dependence of
(R)-()-PPO464 inhibition constants
(Ki(obs)) on dTTP concentrations.
TABLE I
Kinetic and thermodynamic parameters for the interaction of (R)-()-PPO464 with HIV-1 RT wild type and the K103N mutant
RT Kd koff
a kon
b Viral isolate IC50
M s1 M1 s1 M
Wild type 0.025  0.005 1.8  0.2  103 4.5  0.5  104 Wild typec 0.04  0.005
HIV-1 IIIBwtd 0.35  0.02
K103N 0.2  0.01 1.2  0.1  103 0.6  0.01  104 MDRe 3.5  0.3
	H[ter:I]e 	S[ter:I] 	G[ter:I]
kcal  M1 cal  M1  K1 kcal  M1
Wild type 16  0.5 78  1 7.5  0.5
K103N 19  1 79  0.5 5  0.3
a Calculated from Kd  koff/kon.
b Calculated from kapp  kon(Kd  [I]).
c Clinical isolate. The multidrug resistance (MDR) isolate carried the RT mutations M41L/K103N/T215Y.
d Laboratory lymphotropic strain.
e [ter:I], ternary complex (RT  TP  dNTP) bound to the inhibitor. Values are the means of three independent experiments and calculated at T 
300 K. Significance of the differences between the mean values obtained between wild type and K103N RT was p  0.05 according to a Student’s
t test under the null hypothesis that the mean values were equal.
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the wild type and K103N RT could reflect an impaired associ-
ation rate (kon) and/or a faster dissociation rate (koff) of the
inhibitor for the ternary complex of the enzyme with the two
substrates, TP and dNTP. To determine the precise mechanism
of resistance, the apparent binding rates (kapp) for (R)-()-
PPO464 to the wild type and the K103N enzymes were deter-
mined. The corresponding association and dissociation rates
were derived from the relationships kapp  kon(Kd  [I]) and Kd
 koff/kon and are shown in Table I. The comparison between
the different values showed that resistance arose mainly from
a reduced association rate (kon(WT)/kon(mut)  7.5) of the drug to
the K103N mutant, whereas the dissociation rates were com-
parable (koff(WT)/koff(mut)  1.5). These results suggested that
the K103N mutation imposed a thermodynamic barrier to the
binding of the inhibitor. To directly verify this hypothesis, the
thermodynamic parameters for the formation of the
RTTPdNTPI complex were determined from the temperature
dependence of the Kd values. As can be seen from computed
values listed in Table I, the 	H[ter:I] value of the heat change for
complex formation with the K103N mutant was higher than
the one for the wild type enzyme. This translated into a less
negative 	G[ter:I] value for the reaction involving the K103N RT
with respect to WT RT. These results are consistent with the
hypothesis that the K103N mutation imposes a thermody-
namic barrier to inhibitor binding, as reflected by the different
kon values (Table I). This barrier increased the activation en-
ergy for complex formation (	H[ter:I]) and shifted the free en-
ergy (	G[ter:I]) of the system toward less negative values.
(R)-()-PPO464 Displays Synergistic Inhibitory Activity to-
ward WT and K103N HIV-1 Reverse Transcriptase When Com-
bined with NNRTIs and NRTIs—The peculiar mechanism of
action displayed by the (R)-()-PPO464 suggested a possible
synergistic action in combination with other RT inhibitors tar-
geted to different reaction intermediates. We have tested this
hypothesis by challenging recombinant RT, either WT or bear-
ing the K103N mutation, with different double or triple com-
binations of (R)-()-PPO464 with nevirapine and AZT. Nevi-
rapine is an NNRTI that acts as a purely noncompetitive
inhibitor of RT, thus interacting with all of the mechanistic
forms of the enzyme (free RT, binary RTTP, and ternary
RTTPdNTP complexes). AZT is a NRTI and, as such, exclu-
sively targets the binary RTTP complex. As shown by the
combination index values listed in Table IV, (R)-()-PPO464
was found to be significantly synergistic when tested in double
combination with nevirapine, both against WT RT and K103N.
Synergism was also observed toward both enzymes in combi-
TABLE II
Antiviral activity of (R)-()-PPO464, nevirapine (NVP), delavirdine
(DLV), and efavirenz (EFV) toward different clinical isolates
Compound Wild type isolate
a
(ID50)
Resistant (MDR) isolate
(ID50)
M M
(R)-()-PPO464 0.04 3.4  0.2
NVP 0.09 14.8  0.7
DLV 0.04 14.4  0.5
EFV 0.004 4.9  0.5
a Clinical isolate. The multidrug-resistant (MDR) isolate carried the
RT mutations M41L/K103N/T215Y.
TABLE III
Antiviral activity (EC50), cytotoxicity (IC50), and selectivity index (SI)
of (R)-()-PPO464 with different cell lines
Cell line
C8166 U937 Macrophages
EC50 (M) 0.56 0.41 0.57
IC50 (M) 53.9 78.0 58.1
SI 96.2 195 101.9
FIG. 4. Inhibition of the K103N mu-
tant HIV-1 RT by (R)-()-PPO464. As-
says were performed under the conditions
described under “Materials and Meth-
ods.” A, inhibition of HIV-1 RT activity by
the two enantiomers (R)-()-PPO464 (tri-
angles) and (S)-()-PPO463 (circles). B,
plot of the dependence of HIV-1 RT inhi-
bition by (R)-()-PPO464 on the 3-OH
concentration. When points were fitted to
the uncompetitive model of Equation 1,
the SSE were 45.6, 87.2, 13.2, 18, and
12.7, respectively, for the curves obtained
at (R)-()-PPO464 concentrations of 0
(circles), 20 nM (squares), 100 nM (rhom-
bics), 200 nM (triangles), and 400 nM
(closed circles). The SSE for fitting to the
noncompetitive model were 45.5, 135.2,
39.8, 41.2, and 44.6, respectively, whereas
for the competitive model, SSE were 45.8,
158.7, 153.6, 83.1, and 78.3, respectively.
C, plot of the dependence on the (R)-()-
PPO464 concentration of HIV-1 RT Km
(nM) and Vm (pmol  30 min
1) values for
the TTP substrate. Curves were fitted to
the following equations: Km(obs)  Km/-
(1  [I]/Ki) and Vm (obs)  Vm/(1  [I]/Ki).
D, dependence of (R)-()-PPO464 in-
hibition constant (Ki(obs)) on dTTP
concentrations.
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nation with AZTTP. A triple combination of (R)-()-PPO464,
AZTTP, and nevirapine was also synergistic toward both en-
zymes. The derived 50% inhibitory concentrations for each
drug in the combination were compared with the corresponding
values expected under the null reference hypothesis of no in-
teraction. This allowed us to determine the relative contribu-
tion of each drug to the observed synergy. Combination of
(R)-()-PPO464 with nevirapine resulted in a 3–4-fold poten-
tiation of the effect of both drugs in the combination. When the
double (R)-()-PPO464/AZTTP and the triple (R)-()-PPO464/
AZTTP/nevirapine associations were tested, a 2–3-fold poten-
tiation of all drugs was observed, as can be seen from the
comparison of the observed D50 values with the expected ones
under the hypothesis of no interaction.
The significance of the observed synergism was also tested in
drug susceptibility assays using either the wild type laboratory
strain HIV-1 IIIB or the multidrug-resistant (M41L/K103N/
T215Y) clinical isolate. The compound showed a strong syner-
gistic anti-HIV-1 activity when tested in combination with AZT
on both viral strains. Conversely, its effect was antagonistic in
both cases when associated with delavirdine or nevirapine
(Table V).
Pharmacokinetic Studies: Reinvestigation of ()-PPO294
and the Effect of Ritonavir on Pharmacokinetic Parameters of
(R)-()-PPO464—Fig. 5 shows the plasma concentration-time
curves of compound ()-PPO294 after subcutaneous and oral
dosing in rats. Subcutaneous absorption was relatively slow as
indicated by the tmax, which averaged 120 min after a 20 mg/kg
dose. Mean Cmax averaged 3.3  2.9 nmol/ml, and AUCt aver-
aged 345 nmol/mlmin. Other conventional pharmacokinetic
parameters such as clearance, volume of distribution, and elim-
ination t1⁄2 could not be calculated because of the short sampling
interval.
Oral absorption too was relatively slow and variable, with
tmax ranging from 15 to 180 min after 20 mg/kg ()-PPO294.
Mean Cmax averaged 0.3  0.1 nmol/ml; mean AUCt was 42 
16 nmol/mlmin, amounting to about 12% (range 7–18%) of that
after the same dose subcutaneously. The brain-to-plasma dis-
tribution ratio was calculated at the end of the serial blood
sampling and averaged 1.9 regardless of the route of adminis-
tration (range 1.4–2.6).
Preliminary pharmacokinetic studies on (R)-()-PPO464
were done in mice so that only small amounts of the compound
were used. Because combination therapy using HIV-1 protease
inhibitors will be increasingly used but these agents have the
potential to interact with drug-metabolizing enzymes, these
studies also preliminarily assessed how this interaction af-
fected the pharmacokinetics of the new antiviral agent (R)-()-
PPO464. Ritonavir was selected because it is the strongest
inhibitor of P450 enzymes in vitro and in vivo, particularly of
the CYP3A subfamily (28).
When administered alone (20 mg/kg), (R)-()-PPO464 rap-
idly appeared in mouse plasma, reaching mean Cmax within 15
min, as observed for the racemic form at the same dose (15).
Mean Cmax averaged 0.7  0.5 nmol/ml, and mean AUC was 58
nmol/mlmin. When administered with ritonavir (20 mg/kg),
the plasma Cmax was significantly increased to 2.5 nmol/ml
(p  0.01), and AUC increased to 131 nmol/mlmin (data not
shown). Findings were similar in mouse brain, where the com-
pound achieved mean Cmax at 15 min, the same time as in
plasma. Its disappearance then almost paralleled the disap-
pearance from plasma, with comparable elimination t1⁄2 (77
min). Again co-administration with ritonavir increased brain
Cmax (from 2.4 to 7.0 nmol/g; p  0.01) and AUC (from 193 to
418 nmol/gmin), while the mean elimination t1⁄2 remained es-
sentially unchanged (71 min in plasma and 79 min in brain
tissue). The mean brain/plasma AUC ratio of (R)-()-PPO464
averaged 3.3 when administered alone and 3.2 when co-admin-
istered with ritonavir (data not shown).
DISCUSSION
The PPO derivative ()-PPO294 showed a good inhibitory
activity against several NNRTI-resistant mutants (15). To
characterize its mechanism of action, the ()-enantiomer
PPO463 and the ()-enantiomer PPO464 were separated from
the racemic PPO294. The absolute configuration was deter-
mined by x-ray crystallography, and both enantiomers were
tested in inhibition assays against recombinant RT. Only the
(R)-()-PPO464 enantiomer was active, and its mechanism of
inhibition was consistent with specific binding of the molecule
to the ternary complex formed by RT, the template primer, and
the deoxynucleoside triphosphate. Thus, (R)-()-PPO464 is the
first NNRTI described to bind stereoselectively this ternary
complex. The same mechanism of inhibition was observed in
case of the NNRTI-resistant mutant K103N. The loss of activ-
ity of (R)-()-PPO464 toward this mutant was shown to be due
to a thermodynamic barrier, as reflected by the lower associa-
tion rate of the inhibitor to the enzyme and the increased
	H[ter:I] and 	G[ter:I] values for complex formation, with respect
to WT RT. In previous studies, we have shown that the K103N
mutation had the same effects on nevirapine binding (20), thus
suggesting that substitution of Lys103 with an Asn leads to a
TABLE IV
Synergistic interaction of ()-PPO464 with AZTTP and nevirapine against HIV-1 RT wild type and the mutant K103N
Combination
RT wild type K103N
()-PPO464a (D50) NVP
a (D50) AZTTP
a (D50) I50
b ()-PPO464 (D50) NVP (D50) AZTTP (D50) I50
M M
Single 0.04  0.005 0.6  0.1 0.25  0.05 7  0.5
464/NVP
Observedc 0.008  0.001 0.06  0.01 0.3 0.04  0.001 0.5  0.05 0.23
Expectedd 0.024 0.24 1 0.18 1.8 1
Singlee 0.75  0.05e 0.7  0.1 0.033  0.005 1.5  0.05e 3.5  0.5 0.017  0.005
464/AZTTP
Observed 0.02  0.005 0.016  0.002 0.5 0.01  0.005 0.006  0.001 0.36
Expected 0.036 0.034 1 0.016 0.016 1
464/NVP/AZTTP
Observed 0.01  0.002 0.01  0.02 0.01  0.002 0.4 0.006  0.001 0.07  0.01 0.007  0.001 0.4
Expected 0.025 0.22 0.022 1 0.016 0.17 0.015 1
a D50, dose of the inhibitor giving 50% of maximal inhibition under the assay conditions specified calculated according to Equation 7.
b I50, interaction index for 50% inhibition calculated according to Equation 8. For details, see “Material and Methods.”
c Observed D50 values under the experimental conditions utilized.
d Theoretical D50, expected under the null reference hypothesis of no interaction (I50  1), calculated according to Equation 9.
e The experiments with AZTTP were performed in the presence of subsaturating concentrations of the competing dTTP. This explains the lower
potency of ()-PPO464 observed.
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form of RT thermodynamically disfavored for NNRTI binding.
From the recently solved crystallographic structure of the
K103N mutant complexed with efavirenz, it can be seen that
substitution of an Asn leads to the formation of a hydrogen
bond between Asn103 and Lys102, which is not present in the
wild type enzyme (21). These two amino acids line the proposed
entry site for the NNRTIs; thus, the presence of an additional
hydrogen bond can probably confer greater stability to the
uninhibited form of the enzyme, disfavoring the structural
rearrangements that are a consequence of NNRTIs binding.
The structural basis for the absolute preference of (R)-()-
PPO464 for the ternary complex is less clear. By comparing the
structures of the unliganded enzyme with those of the enzyme-
DNA and enzyme-DNA-dNTP complexes, the major observed
differences were movements of the fingers and thumb subdo-
mains (22–25). Since NNRTI binding involves a rearrangement
of the structural elements surrounding the binding pocket, it is
possible that local differences might facilitate the access of
(R)-()-PPO464 to the binding site, partially explaining the
observed mechanism of inhibition. Other second generation
NNRTIs have been shown to bind with variable affinities to
different reaction intermediates (26, 27); moreover, in a previ-
ous work, we have shown that the second generation NNRTI
efavirenz displays preferential affinity for either the binary or
the ternary complex of RT with its substrates, with respect to
the unliganded enzyme (28). Thus, it is conceivable to propose
an induced fit mechanism for binding of some classes of NNR-
TIs, which is triggered by complex formation among RT and the
TP and dNTP substrates. This specificity is absolute in the case
of (R)-()-PPO464, which binds exclusively the ternary com-
plex. The selective targeting of NNRTIs to different mechanis-
tic forms of the enzyme can provide the rationale for a new
approach in combination chemotherapy. Associations of NRTIs
and NNRTIs able to specifically inhibit different enzymatic
forms within the reaction pathway are expected to avoid an-
tagonistic effects, due to competition among the inhibitors for
the same form of the enzyme, and to enhance synergistic ac-
tivity. The results of combinations of (R)-()-PPO464 with NR-
TIs and NNRTIs presented in this study support this view. The
observed antagonistic effect of (R)-()-PPO464 in combination
with delavirdine or nevirapine in infected cell-based assays
(Table IV) might suggest a possible competition of (R)-()-
PPO464 and these NNRTIs for a common metabolic pathway
(e.g. intracellular import), since they have been found to act
synergistically at the level of their molecular target (Table III).
The pharmacokinetic results of the present study confirm
and extend previous findings on the disposition of compound
()-PPO294 in rodents, evidencing differences and similarities
between species and between the racemate and its active iso-
mer (R)-()-PPO464 (15). The mean relative bioavailability
amounted to only about 12% in rats compared with about 30%
in mice (15). However, presystemic metabolism may substan-
tially differ from one species to another (29). In mice, the mean
oral bioavailability, in terms of Cmax and AUC, was slightly
higher for the (R)-(-)-PPO464 (present data) than for the cor-
responding racemate (15). This suggests that the pharmacoki-
netics of ()-PPO294 may be governed by stereoselectivity, the
()-isomer undergoing more marked presystemic metabolism
than the active ()-isomer. Interestingly, ritonavir increased
the Cmax and AUC of the (R)-()-PPO464 while having little
effect on its plasma and brain elimination t1⁄2 after oral dosing.
This metabolic interaction is likely to be mainly due to inhibi-
tion of P450 enzymes, particularly members of the CYP3A
subfamily (30). Because HIV-1 replicates in the central nervous
system, the antiretroviral therapy needs to consider whether
drugs adequately cross the blood-brain barrier. The present
study shows that (R)-()-PPO464 easily crosses the blood-brain
barrier in rodents, approaching micromolar concentrations at a
site of infection and viral replication for HIV-1 after a 20 mg/kg
dose. Transport of (R)-()-PPO464 across the blood-brain bar-
rier may occur by passive diffusion (31). This is supported by
the observation that ritonavir did not alter the brain-to-plasma
distribution ratio of (R)-()-PPO464 in mice. This PI was an
excellent substrate and potent inhibitor of P-glycoprotein (30,
32, 33), a membrane-localized drug transport mechanism ex-
pressed at the blood-brain barrier (34–36). The detailed knowl-
TABLE V
Synergy determination of (R)-()-PPO464 activity in combination with AZT, NVP, and DLV against HIV IIIB wild type laboratory strain and a
multidrug-resistant (MDR) clinical isolate
Compounds
ID50 of
compounds
alone
ID50 of
compounds in
combination with
PPO464
ID50 of
PPO464 in
combination
with
compounds
CIa
(nonmutually
exclusive
assumption)
CI (mutually
exclusive
assumption)
Interaction
index (I)b
M M M
Nonec NAd NA 0.56 NA NA
Nonee NA NA 2
AZTc 0.06c 0.016c 0.20c 0.71c 0.61c
AZTe 0.5e 0.12e 0.13e 0.3e
Delavirdinec 0.04c 0.026c 0.99c 3.6c 2.4c
Nevirapinee 7.5e 7.4e 1.85d 1.9e
a CI  1, CI  1, and CI  1 indicate antagonistic, additive, and synergistic activities, respectively. The CI values were calculated at 50%
antiviral activity using both the mutually nonexclusive and the mutually exclusive form of the equation of Chou and Talalay (18, 19), as described
under “Material and Methods.”
b I  1, I  1, and I  1 indicate antagonistic, additive, and synergistic activities, respectively. The I values were calculated at 50% antiviral
activity using the Berenbaum’s index algorithm according to the modifications of Greco et al. (17), as described under “Material and Methods.”
c Against the HIV IIIB wild type strain.
d NA, not applicable.
e Against the MDR M41L/K103N/T215Y clinical isolate.
FIG. 5. Mean plasma concentration-time curves of compound
()-PPO294 after a subcutaneous (open squares; n  3) and oral
(closed squares; n  4) dose of 20 mg/kg in rats.
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edge of the mechanism of inhibition of (R)-()-PPO464, its
pharmacokinetic properties, and its interaction with other an-
ti-RT drugs provides the necessary background for the devel-
opment of novel third generation NNRTIs.
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